ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2041

Epigenome-wide Association Study Reveals Differential DNA Methylation in Systemic Lupus Erythematosus Patients with a History of Ischemic Heart Disease

Juliana Imgenberg-Kreuz1, Christopher Sjöwall 2, Martina Frodlund 2, Iva Gunnarsson 3, Elisabet Svenungsson 4 and Dag Leonard 1, 1Department of Medical Sciences, Section of Rheumatology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden, 2Department of Clinical and Experimental Medicine, Rheumatology/Division of Neuro and Inflammation Sciences, Linköping University, Linköping, Sweden, 3Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 4Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Cardiovascular disease, DNA Methylation, myocardial involvement and interferons, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: SLE – Etiology & Pathogenesis Poster II

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of ischemic heart disease (IHD). Altered methylation patterns have been reported both in SLE, including hypomethylation of interferon (IFN) regulated genes, and in individuals with a history of IHD in the general population. We performed a matched case-case epigenome-wide association study (EWAS) for IHD in patients with SLE to identify phenotype-specific differences in DNA methylation.

Methods: DNA methylation profiles from peripheral blood samples of 33 SLE patients with a history of IHD (myocardial infarction and or angina pectoris) and 66 matched (ethnicity and age) SLE patients without any prior cardiovascular events were generated on the HumanMethylation450k array (Illumina). All patients were female, fulfilled ≥ 4 ACR-82 SLE criteria and were recruited at the Uppsala, Linköping and Karolinska University hospitals, Sweden. Association was tested using a logistic regression model including age at sampling, blood cell type distribution and HM450k BeadChip as covariates. Differentially methylated CpG sites (DMCs) were defined as p< 1.3×10-7 based on Bonferroni correction and an absolute average difference in methylation beta of |Δβ| >0.05. Functional gene-set enrichment analyses were conducted using the ToppGene Suite database and for classification of IFN regulated genes the Interferome v2.01 database was queried.

Results: We identified 210 DMCs in SLE IHD, with a majority (84.3%) of DMCs showing decreased methylation levels in IHD. The strongest differentially methylated DMCs were located at Complement component 4 binding protein alpha (C4BPA) (|Δβ|=-0.06, p=1.1×10-13), Membrane spanning 4-domains A3 (MS4A3) (|Δβ|=-0.07, p=3.7×10-13) and Triggering receptor expressed on myeloid cells 1 (TREM1) (|Δβ|=-0.07, p=8.7×10-13). Further, a differentially methylated region with multiple DMCs was observed in the promoter region of Programmed cell death 1 gene (PDCD1). DMCs in SLE IHD were annotated to 155 unique genes, of which 63.9% were characterized as interferon-induced. Gene-set enrichment analysis revealed response to oxidative stress (p=1.0×10-5), vesicle-mediated transport (p=1.1×10-6) and inflammasomes (p=6.4×10-6) as the most significantly enriched pathways in SLE IHD.

Conclusion: The results of this study highlight genes and pathways that may be implicated in the pathogenesis of and/or recovery from IHD in patients with SLE. The identified DMCs can serve as candidates for functional studies and as potential biomarkers for IHD in patients with SLE.


Disclosure: J. Imgenberg-Kreuz, None; C. Sjöwall, None; M. Frodlund, None; I. Gunnarsson, None; E. Svenungsson, None; D. Leonard, None.

To cite this abstract in AMA style:

Imgenberg-Kreuz J, Sjöwall C, Frodlund M, Gunnarsson I, Svenungsson E, Leonard D. Epigenome-wide Association Study Reveals Differential DNA Methylation in Systemic Lupus Erythematosus Patients with a History of Ischemic Heart Disease [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/epigenome-wide-association-study-reveals-differential-dna-methylation-in-systemic-lupus-erythematosus-patients-with-a-history-of-ischemic-heart-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/epigenome-wide-association-study-reveals-differential-dna-methylation-in-systemic-lupus-erythematosus-patients-with-a-history-of-ischemic-heart-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology